PRN: Research and Markets - Global T-Cell Immunotherapy Pipeline Analysis 2016-2017: Novartis, Kite Pharma, Juno Therapeutics, and Sorrent Therapeutics are Actively Involved

10/mar/2017 17:15:12 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 6 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Research and Markets - Global T-Cell Immunotherapy Pipeline Analysis 2016-2017: Novartis, Kite Pharma, Juno Therapeutics, and Sorrent Therapeutics are Actively Involved

 
[10-March-2017]
 

DUBLIN, Mar 10, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global T-Cell Immunotherapy Pipeline Analysis, 2016" report to their offering.

The T-cell immunotherapy pipeline is very strong with a total of 139 drug candidates. Pharma giant such as Novartis, Kite Pharmaceuticals, Juno Therapeutics, Inc. and Sorrent Therapeutics, Inc. are actively involved in development of these therapeutics. There are 16 drug candidates in Phase II stage of development, 36 in Phase I, and seven in Phase 0. Two drug candidates have been filed for Investigational New Drug (IND) application, and there are 78 drugs in Pre-clinical and Discovery stage.

NY-ESO-1 is under Phase II stage of development by Kite Pharmaceuticals Inc. for the treatment of solid tumors including, but not limited to sarcoma, bladder cancer, esophageal carcinoma, non-small cell lung cancer, breast carcinoma, ovarian carcinoma, prostate carcinoma, multiple myeloma, hepatocellular carcinoma and melanoma. The therapeutic candidate targets NY-ESO-1 antigen and being produced by using Engineered Autologous Cell Therapy (eACT) technology. In addition, CA! RT-EGFR, also known as Anti-EFGR-CAR vector-transduced T-cells, is under Phase I/II stage of development by Cellular Biomedicine Group Inc. for the treatment of advanced EGFR-positive solid tumors.

Several companies are involved in T-cell immunotherapy, with their products in different phases. Sorrento Therapeutics, Inc. is developing 21 products based on CAR T-cell therapy. The company is using CAR.TNK technology platform and G-MAB fully human antibody technology for the development of its therapeutic candidates. Novartis Pharmaceuticals has nine products in their pipeline and one drug candidate reached into Phase II clinical stage.

Some of the key players developing T-cell immunotherapies are

  • Novartis Ag
  • Cellular Biomedicine Group, Inc.
  • Kite Pharmaceuticals Inc.
  • Juno Therapeutics, Inc.
  • Gradalis, Inc.
  • Atara Biotherapeutics, Inc.
  • Adaptimmune Therapeutics Plc.
  • Immunocore Limited
  • Lion Biotechnologies, Inc.

Key Topics Covered:

1. Research Scope And Methodology

2. Executive Summary

3. Pipeline Outlook

4. Global T-Cell Immunotherpay Pipeline Analysis By Phase

5. Swot Analysis Of T-Cell Immunotherapy Pipeline

6. Company Profiles And Strategic Developments

7. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/kstjs9/global_tcell

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl